A Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Evogliptin After Oral Administration in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Diet and Exercise
Latest Information Update: 31 Jul 2021
At a glance
- Drugs Evogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Dong-A ST
- 22 Jul 2021 Results of a meta-analysis of six randomized controlled trials assessing evogliptin versus placebo and versus other DPP-4 inhibitors conducted following the development of evogliptin, published in the Clinical Therapeutics
- 18 Oct 2016 New trial record
- 16 Sep 2016 Primary endpoint (Mean changes from baseline in hemoglobin A1c (HbA1c)) has been met according to the results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.